Show simple item record

dc.contributor.authorHartmann, Marion C.
dc.contributor.authorDwyer, Róisín M.
dc.contributor.authorCostello, M.
dc.contributor.authorPotter, Shirley M.
dc.contributor.authorCurran, Catherine E.
dc.contributor.authorHennessy, Emer
dc.contributor.authorNewell, John
dc.contributor.authorGriffin, Damian G.
dc.contributor.authorKerin, Michael J.
dc.identifier.citationHartmann, M. C., Dwyer, R. M., Costello, M., Potter, S. M., Curran, C., Hennessy, E., Newell, J., Griffin, D. G., Kerin, M. J. (2011). Relationship between CCL5 and transforming growth factor-β1 (TGFβ1) in breast cancer. European Journal of Cancer, 47(11), 1669-1675. doi:
dc.description.abstractPurpose Investigate circulating CCL5 in breast cancer patients and healthy controls, along with gene expression levels in corresponding tumour tissue and isolated primary stromal cells. Hormonal control of CCL5, and a potential relationship with TGFβ1, was also investigated. Methods Circulating levels of CCL5 and TGFβ1 were measured in 102 breast cancer patients and 66 controls using ELISA. Gene expression levels (CCL5, CCR5, TGFβ1, TGFβRII) were quantified in corresponding tumour tissue (n = 43), normal tissue (n = 16), and isolated tumour (n = 22) and normal (n = 3) stromal cells using RQ-PCR. CCL5 and circulating menstrual hormones (LH, FSH, Oestradiol, Progesterone) were analysed in serum samples from healthy, premenopausal volunteers (n = 60). Results TGFβ1 was significantly higher in breast cancer patients (Mean(SEM) 27.4(0.9) ng/ml) compared to controls (14.9(0.9) ng/ml). CCL5 levels decreased in the transition from node negative (59.6(3.7) ng/ml) to node positive disease (40.5(6.3) ng/ml) and increased again as the number of positive lymph nodes increased (⩾3 positive 50.95(9.8) ng/ml). A significant positive correlation between circulating CCL5 and TGFβ1 (r = 0.423, p < 0.0001) was observed, and mirrored at the gene expression level in tumour tissue from the same patients (r = 0.44, p < 0.001). CCL5, CCR5 and TGFβ1 expression was significantly higher in tumour compared to normal breast tissue (p < 0.001). A significant negative correlation was observed between circulating CCL5, Oestradiol and Progesterone (r = −0.50, r = −0.39, respectively, p < 0.05). Conclusion CCL5 expression is elevated in the tumour microenvironment. The data support a role for hormonal control of circulating CCL5 and also highlight a potentially important relationship between CCL5 and TGFβ1 in breast cancer.en_IE
dc.description.sponsorshipThis study was supported by funding from the National Breast Cancer Research Institute (NBCRI), a Breast Cancer Ireland Research Fellowship Award (M.C. Hartmann), and the Health Research Board of Ireland (R.M. Dwyer, J. Newell).en_IE
dc.relation.ispartofEuropean Journal Of Canceren
dc.subjectBreast canceren_IE
dc.subjectMenstrual hormonesen_IE
dc.subjectStromal–epithelial interactionen_IE
dc.titleRelationship between CCL5 and transforming growth factor-β1 (TGFβ1) in breast canceren_IE
dc.contributor.funderNational Breast Cancer Research Instituteen_IE
dc.local.contactRóisín Dwyer, Surgery, Nui Galway. 3008 Email:

Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:


This item appears in the following Collection(s)

Show simple item record